Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma in Situ 1Breast Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 3Paclitaxel 3Carboplatin 3niraparib 2anlotinib 2Pemetrexed 2Palliative Care 2Interviews as Topic 2Gemcitabine 2Educational Status 2Bevacizumab 2temsirolimus 1relacorilant 1olaparib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1Watchful Waiting 1Transurethral Resection of Prostate 1Topotecan 1Therapeutic Touch 1Radiotherapy 1Pregnancy Tests 1Ocoxin 1Nivolumab 1Methods 1Laparoscopy 1Human Papillomavirus DNA Tests 1Fulvestrant 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × Electrocardiography × Gynecologic × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡